Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up

Fig. 5

a–c Cumulative incidence of breast cancer (BC)-related events (BCFi) stratified by treatment allocation (control vs. TAM) for patients whose tumours were ER-positive and had a low TILs (< 10%); b intermediate TILs (10–49%) and c high TILs (≥ 50%). Abbreviations: BCFi breast cancer-free interval, ER oestrogen receptor, TAM tamoxifen, TILs tumour-infiltrating lymphocytes

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us